Sign In
Buy SGMT
$6.86
+0.0700 (+1.03%)
At Close: Jun 03, 2026
Sagimet Biosciences Inc. (SGMT) Upgraded to Buy: What Does It Mean for the Stock?
01:01pm, Wednesday, 20'th Aug 2025
Sagimet Biosciences Inc. (SGMT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
After Plunging 28% in 4 Weeks, Here's Why the Trend Might Reverse for Sagimet Biosciences Inc. (SGMT)
10:36am, Wednesday, 20'th Aug 2025
The heavy selling pressure might have exhausted for Sagimet Biosciences Inc. (SGMT) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall S
Sagimet Biosciences Reports Second Quarter 2025 Financial Results and Provides Corporate Updates
07:30am, Wednesday, 13'th Aug 2025
Denifanstat met all primary and secondary endpoints in Phase 3 clinical trial in moderate to severe acne conducted by license partner Ascletis in China
Sagimet Biosciences to Participate in the Canaccord Genuity 45th Annual Growth Conference
07:00am, Tuesday, 05'th Aug 2025
SAN MATEO, Calif., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metaboli
What Makes Sagimet Biosciences Inc. (SGMT) a Strong Momentum Stock: Buy Now?
01:00pm, Wednesday, 11'th Jun 2025
Does Sagimet Biosciences Inc. (SGMT) have what it takes to be a top stock pick for momentum investors? Let's find out.
Wall Street Analysts Predict a 437.05% Upside in Sagimet Biosciences Inc. (SGMT): Here's What You Should Know
11:01am, Monday, 09'th Jun 2025
The mean of analysts' price targets for Sagimet Biosciences Inc. (SGMT) points to a 437.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreem
SAN MATEO, Calif., June 09, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metaboli
Sagimet: Positive China Partner Acne Vulgaris Data Bodes Well For TVB-3567
01:45pm, Wednesday, 04'th Jun 2025
Sagimet Biosciences' partner Ascletis reported strong phase 3 results for denifanstat in moderate-to-severe acne, validating FASN inhibition as a novel oral treatment. Sagimet is advancing next-gen FA
Sagimet Biosciences Announces Positive Phase 3 Results for Denifanstat for the Treatment of Moderate-to-Severe Acne from Partner Ascletis
05:00am, Wednesday, 04'th Jun 2025
Denifanstat met all primary and secondary endpoints versus placebo Denifanstat was well tolerated Oral FASN inhibitors offer a novel mechanism of action for the potential treatment of moderate to seve
SAN MATEO, Calif., May 22, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic
Sagimet Biosciences Reports First Quarter 2025 Financial Results and Provides Corporate Updates
06:00am, Thursday, 08'th May 2025
Phase 1 clinical trial to evaluate the pharmacokinetics (PK) of a combination of denifanstat and resmetirom expected to initiate in 2H 2025; data readout expected 1H 2026 Phase 1 clinical trial to ev
Sagimet Biosciences Reports Full Year 2024 Financial Results and Provides Corporate Updates
07:30am, Wednesday, 12'th Mar 2025
Denifanstat Phase 3 MASH program initiated in Q4 2024; patient screening expected to start in 1H 2025 Denifanstat received Breakthrough Therapy designation from FDA for MASH Clearance of Investigation
Sagimet Biosciences Announces Clearance of IND for FASN Inhibitor TVB-3567, to be Developed for the Treatment of Acne
08:00am, Tuesday, 11'th Mar 2025
TVB-3567 is the Company's second fatty acid synthase (FASN) inhibitor First-in-human Phase 1 trial initiation planned in 2025 SAN MATEO, Calif., March 11, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences
Sagimet Biosciences' Denifanstat Should Be Worth More Today
04:27pm, Friday, 07'th Mar 2025
Denifanstat is SGMT's leading FASN inhibitor for MASH. It has shown strong Phase 2b results and earned the FDA Breakthrough Therapy designation. SGMT also has a diversified pipeline on acne, solid tum
Sagimet: More Than Just A MASH Drug Development Biotech
03:56pm, Thursday, 14'th Nov 2024
Sagimet Biosciences Inc.'s Initiation of the phase 3 FASCINIT and FASCINATE-3 studies, using denifanstat for treatment of patients with MASH/MAFLD & MASH respectively, expected before the end of 2024.
